氟比洛芬酯复合布托啡诺、吗啡用于晚期癌症患者自控镇痛

Efficacy of patient-controlled analgesia with flurbiprofen axetil and butorphanol/morphine in patients with advanced cancer

目的观察晚期癌症患者自控静脉镇痛（patient-controlled intravenous analgesia,PCIA）中氟比洛芬酯复合布托啡诺、吗啡的镇痛效果。方法 40例Ⅱ~Ⅲ级晚期癌症患者应用PCIA镇痛,分为两组：氟比洛芬酯＋布托啡诺组（B组）、氟比洛芬酯＋吗啡组（M组）,观察48h内（6h,12h,24h,48h）的镇痛、镇静评分及不良反应发生情况。结果 48h内的VAS评分和镇静评分,两组间无显著差异（P〉0.05）,B组患者不良反应的发生率明显少于M组。结论氟比洛芬酯复合布托啡诺用于晚期癌症自控镇痛的效果良好,且不良反应低于吗啡。

Objective To compare the analgesic effect of flurbiprofen axetil and butorphanol/morphine during patient-controlled intravenous analgesia（PCIA）in patients with advanced cancer.Methods Totally 40 patients with Ⅱ ~ Ⅲ-class advanced cancer were randomly divided into two PCIA groups according to different analgesic drugs with 20 cases in each group：flurbiprofen axetil ＋ butorphanol group（B group）,flurbiprofen axetil ＋ morphine group（M group）.The Analgesia efficiency,sedation efficiency,life sign and side effect were observed for 48 hours（6 h,12 h,24 h,4 8 h）.Results No statistical difference in the analgesic effect was found between the two groups（P0.05）.Patients of B group had fewer incidences of adverse events than those of M group.Conclusion Patient-controlled intravenous analgesia with flurbiprofen axetil combined with butorphanol has satisfactory analgesic effect and fewer side effects in patients with advanced cancer.